Can cetuximab affect paraneoplastic myopathy?

J Neurooncol. 2009 Jul;93(3):437-8. doi: 10.1007/s11060-009-9795-6. Epub 2009 Jan 22.

Abstract

Cetuximab given concurrently with chemotherapy has shown survival benefit for patients with metastatic colon cancer. We report a case of a patient with metastatic colon cancer who developed paraneoplastic necrotizing myopathy that possibly responded to cetuximab despite lack of improvement of the underlying cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / complications
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Candidiasis / complications
  • Candidiasis / drug therapy
  • Cetuximab
  • Colonic Neoplasms / complications
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / pathology
  • Humans
  • Irinotecan
  • Klebsiella Infections / complications
  • Klebsiella Infections / drug therapy
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Muscular Diseases / drug therapy*
  • Muscular Diseases / etiology
  • Muscular Diseases / physiopathology
  • Paraneoplastic Syndromes / drug therapy*
  • Paraneoplastic Syndromes / etiology
  • Paraneoplastic Syndromes / physiopathology
  • Tuberculosis / complications
  • Tuberculosis / drug therapy

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Irinotecan
  • Cetuximab
  • Methylprednisolone
  • Camptothecin